Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled study of BMS-986322 in moderate-to-severe plaque psoriasis
jRCT2031230177Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of lomedeucitinib in plaque psoriasis (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Proportion of participants achieving 75% reduction in PASI score (PASI-75), Number of participants with treatment-emergent adverse events (TEAEs) and 6 more. Started Jul 2023; status: completed.
02
Drugs
lomedeucitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2031230177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230177.